{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-006317","form_type":"8-K","ticker":"INBS","cik":"0001725430","company_name":"INTELLIGENT BIO SOLUTIONS INC.","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.011312+00:00","generated_at":"2026-05-16T03:04:44.818717+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Intelligent Bio Solutions Q2 revenue $896,774, up 48% YoY; reader sales surge 104%","bullets":["Q2 total revenue $896,774, up 48% YoY; reader sales $246,519 (+104%), cartridge sales $516,754 (+33%).","First-half FY2026 revenue $2.01M (+36% YoY); gross margin improved to 49% from 39%.","Closed $10M private placement (net $9.4M received Jan 2, 2026) for working capital and FDA 510(k) submission.","Initiated additional clinical studies for FDA 510(k); plans for U.S. market entry.","Strategic alliance with Vlepis Pty Ltd for consumer health monitoring; major industrial service contract."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-006317","json":"https://secwatch.observer/filing/0001493152-26-006317.json","markdown":"https://secwatch.observer/filing/0001493152-26-006317.md","text":"https://secwatch.observer/filing/0001493152-26-006317.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725430/000149315226006317/0001493152-26-006317-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725430/000149315226006317/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:04:44.818717+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}